Streptococcus pneumoniae serotype 3

Phase 3Biologic

Streptococcus pneumoniae serotype 3 is one of 4 biologic programs targeting Pneumococcal Vaccines. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pneumococcal VaccinesRecruiting

Pneumococcal VaccinesPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Pneumococcal Vaccines

#DrugCompanyPhaseTrials

Seasonal Influenza Vaccine

Novartis

Phase 3

1 2

PCV15

Merck & Co.

Phase 3

1 3

31-Valent Pneumococcal Conjugate Vaccine

VVaxcyte, Inc.

Phase 3

2 4

Streptococcus pneumoniae serotype 3

UUniversity of Oxford

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Pneumococcal Vaccines

NCT06731374

Clinical

Trials by Indication[1]

Pneumococcal Vaccines1 trial

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

Recruiting·UUniversity of Oxford·Phase 4·NCT06731374·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Streptococcus pneumoniae serotype 3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Streptococcus pneumoniae serotype 3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Streptococcus pneumoniae serotype 3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Oxford company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Oxford

Streptococcus pneumoniae serotype 3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pneumococcal Vaccines1 trial

References

Drug Info

Quick Facts

Related News